Lewy Body Dementia (LBD) Overview
Learn About Lewy Body Dementia (LBD)
- Lewy body dementia
- Autosomal dominant diffuse Lewy body disease
- DLB
- Diffuse Lewy body disease
- Lewy body disease
Johns Hopkins Outpatient Center
Dr. Scholz is a neurologist and geneticist specializing in neurodegenerative disorders such as Parkinson's disease, atypical parkinsonism and dementia syndromes. She received her medical degree from the Medical University Innsbruck, Austria. Following graduation, she was a postdoctoral fellow at the National Institutes of Health under the supervision of Drs. Andrew Singleton and John Hardy. She obtained a Ph.D. in neurogenomics from the University College London, UK in 2010. She then moved to Baltimore to complete her neurology residency training at Johns Hopkins. In 2015 Dr. Scholz received the McFarland Transition to Independence Award for Neurologist-Scientists. She is Lasker Clinical Research Scholar at the National Institute of Neurological Disorders and Stroke focusing on genetic causes of neurodegenerative syndromes, and an adjunct faculty member at Johns Hopkins' department of neurology. Dr. Scholz is rated as an Elite provider by MediFind in the treatment of Lewy Body Dementia (LBD). Her top areas of expertise are Lewy Body Dementia (LBD), Multiple System Atrophy, Movement Disorders, and Parkinson's Disease.
Penn Neurology Pennsylvania Hospital
Andrew Siderowf is a Neurologist in Philadelphia, Pennsylvania. Dr. Siderowf is rated as an Elite provider by MediFind in the treatment of Lewy Body Dementia (LBD). His top areas of expertise are Parkinson's Disease, Movement Disorders, Lewy Body Dementia (LBD), and Dementia. Dr. Siderowf is currently accepting new patients.
Penn Neurology Pennsylvania Hospital
Alice Chen is a Neurologist in Philadelphia, Pennsylvania. Dr. Chen is rated as an Elite provider by MediFind in the treatment of Lewy Body Dementia (LBD). Her top areas of expertise are Parkinson's Disease, Movement Disorders, Lewy Body Dementia (LBD), and Dementia.
Summary: The proposed study aims to address the critical gaps in understanding the mechanisms of CF (Cognitive Fluctuations) by leveraging recently emerged molecular biomarkers, advanced neuroimaging techniques to assess measures of cholinergic degeneration, and synchronous EEG and assessments of attention. One of the overarching innovations of study is combining all of these assessments into one integrate...
Summary: Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center